{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:25Z","timestamp":1792787905054,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal","id":[{"id":"https:\/\/ror.org\/02xzytt36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tacrolimus, a primary immunosuppressant in kidney transplantation, exhibits variable pharmacokinetics. While model-informed precision dosing (MIPD) using population pharmacokinetic (PopPK) models improve dosing accuracy, models developed in specific populations lack applicability in other populations. We aimed to evaluate the predictive performance of published models integrated in clinical decision support systems (CDSS) in Indian adult renal transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Predictive performance of four published PopPK models were evaluated using an independent dataset of 120 trough concentrations from 60 adult renal transplant recipients. Models were assessed using prediction based and simulation-based diagnostics. Maximum\n                      <jats:italic>a posteriori<\/jats:italic>\n                      (MAP) Bayesian prediction was also used to evaluate the model performance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A priori predictions (PRED) for all four models demonstrated systematic underprediction, with relative mean prediction error (rME) ranging from \u2212\u200925.0% to -64.0%, failing clinical acceptability thresholds. However, integrating patient-specific data via MAP Bayesian estimation corrected this bias and improved precision. Notably, all models achieved higher accuracy and precision, with more than 60% of individual predictions falling within\n                      <jats:inline-formula>\n                        <jats:tex-math>$$\\:\\pm\\:20\\text{\\%}$$<\/jats:tex-math>\n                      <\/jats:inline-formula>\n                      (\n                      <jats:inline-formula>\n                        <jats:tex-math>$$\\:{F}_{20}$$<\/jats:tex-math>\n                      <\/jats:inline-formula>\n                      ) of the observed values. Additionally, scaling down the clearance parameter by 30% mitigated the systematic bias observed in the initial a priori predictions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Published PopPK models exhibited significant systematic bias when applied to Indian renal transplant recipients, posing a substantial risk of overdosing if used without adjustment for initial dose selection. However, these models adapted using MAP Bayesian approach or scaling of clearance parameter demonstrate better predictive performance in this cohort, suggesting they can guide proactive precision dosing in the Indian cohort. Prospective studies evaluating the target attainment and clinical outcomes are required to establish their clinical applicability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05214-3","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:43:39Z","timestamp":1784713419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["External evaluation of population pharmacokinetic models for tacrolimus in kidney transplant recipients: implications for model-informed precision dosing"],"prefix":"10.1186","volume":"27","author":[{"given":"Arun Prasath","family":"Raju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Naithani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh","family":"Kenwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Kumar","family":"SP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita Verma","family":"Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra Prabhu","family":"Attur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadev","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Pattanaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surulivelrajan","family":"Mallayasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"5214_CR1","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/ajhp\/52.14.1521","volume":"52","author":"PA Kelly","year":"1995","unstructured":"Kelly PA, Burckart GJ, Venkataramanan R, Tacrolimus. A new immunosuppressive agent. Am J Health-System Pharm. 1995;52:1521\u201335. https:\/\/doi.org\/10.1093\/ajhp\/52.14.1521.","journal-title":"Am J Health-System Pharm"},{"key":"5214_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, Van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report. Ther Drug Monit. 2019;41:261\u2013307. https:\/\/doi.org\/10.1097\/FTD.0000000000000640.","journal-title":"Ther Drug Monit"},{"key":"5214_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404\u201330. https:\/\/doi.org\/10.2165\/00003088-199529060-00003.","journal-title":"Clin Pharmacokinet"},{"key":"5214_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","volume":"53","author":"DA Hesselink","year":"2014","unstructured":"Hesselink DA, Bouamar R, Elens L, Van Schaik RHN, Van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53:123\u201339. https:\/\/doi.org\/10.1007\/s40262-013-0120-3.","journal-title":"Clin Pharmacokinet"},{"key":"5214_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"T Vanhove","year":"2016","unstructured":"Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: A mechanistic review. Drug Metabolism Reviews Taylor Francis. 2016;48:88\u2013112. https:\/\/doi.org\/10.3109\/03602532.2016.1151037.","journal-title":"Drug Metabolism Reviews Taylor Francis"},{"key":"5214_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"K Birdwell","year":"2015","unstructured":"Birdwell K, Decker B, Barbarino J, Peterson J, Stein C, Sadee W, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98:19\u201324. https:\/\/doi.org\/10.1002\/cpt.113.","journal-title":"Clin Pharmacol Ther"},{"key":"5214_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/tpj.2015.99","volume":"17","author":"Y Choi","year":"2017","unstructured":"Choi Y, Jiang F, An H, Park HJ, Choi JH, Lee H. A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM plus platform. Pharmacogenomics J. 2017;17:174\u20139. https:\/\/doi.org\/10.1038\/tpj.2015.99.","journal-title":"Pharmacogenomics J"},{"key":"5214_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jcph.1325","volume":"59","author":"O Campagne","year":"2019","unstructured":"Campagne O, Mager DE, Tornatore KM. Population pharmacokinetics of tacrolimus in transplant recipients: What did we learn about sources of interindividual variabilities? J Clin Pharmacol. 2019;59:309\u201325. https:\/\/doi.org\/10.1002\/jcph.1325.","journal-title":"J Clin Pharmacol"},{"key":"5214_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/jcph.1823","volume":"61","author":"M Al-Kofahi","year":"2021","unstructured":"Al-Kofahi M, Oetting WS, Schladt DP, Remmel RP, Guan W, Wu B, et al. Precision dosing for tacrolimus using genotypes and clinical factors in kidney transplant recipients of european ancestry. J Clin Pharmacol. 2021;61:1035\u201344. https:\/\/doi.org\/10.1002\/jcph.1823.","journal-title":"J Clin Pharmacol"},{"key":"5214_CR10","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1111\/bcp.16203","volume":"90","author":"D Khatri","year":"2024","unstructured":"Khatri D, Felmingham B, Moore C, Lazaraki S, Stenta T, Collier L, et al. Evaluating the evidence for genotype-informed bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review. Br J Clin Pharmacol. 2024;90:2724\u201341. https:\/\/doi.org\/10.1111\/bcp.16203.","journal-title":"Br J Clin Pharmacol"},{"key":"5214_CR11","doi-asserted-by":"publisher","first-page":"105237","DOI":"10.1016\/j.ejps.2020.105237","volume":"145","author":"X Cai","year":"2020","unstructured":"Cai X, Li R, Sheng C, Tao Y, Zhang Q, Zhang X, et al. Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients. Eur J Pharm Sci. 2020;145:105237. https:\/\/doi.org\/10.1016\/j.ejps.2020.105237.","journal-title":"Eur J Pharm Sci"},{"key":"5214_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.kint.2023.06.021","volume":"104","author":"N Lloberas","year":"2023","unstructured":"Lloberas N, Griny\u00f3 JM, Colom H, Vidal-Alabr\u00f3 A, Fontova P, Rigo-Bonnin R, et al. A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based bayesian prediction. Kidney Int. 2023;104:840\u201350. https:\/\/doi.org\/10.1016\/j.kint.2023.06.021.","journal-title":"Kidney Int"},{"key":"5214_CR13","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1111\/ajt.13691","volume":"16","author":"N Shuker","year":"2016","unstructured":"Shuker N, Bouamar R, van Schaik RHN, Clahsen-van Groningen MC, Damman J, Baan CC, et al. A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg. 2016;16:2085\u201396. https:\/\/doi.org\/10.1111\/ajt.13691.","journal-title":"Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg"},{"key":"5214_CR14","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1111\/j.1523-1755.2005.00352.x","volume":"67","author":"EM Scholten","year":"2005","unstructured":"Scholten EM, Cremers SCLM, Schoemaker RC, Rowshani AT, Van Kan EJ, Den Hartigh JAN, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440\u20137. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00352.x.","journal-title":"Kidney Int"},{"key":"5214_CR15","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1111\/ajt.13803","volume":"16","author":"T Vanhove","year":"2016","unstructured":"Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ. High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients. Am J Transplant. 2016;16:2954\u201363. https:\/\/doi.org\/10.1111\/ajt.13803.","journal-title":"Am J Transplant"},{"key":"5214_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/psp4.12758","volume":"11","author":"R Faelens","year":"2022","unstructured":"Faelens R, Luyckx N, Kuypers D, Bouillon T, Annaert P. Predicting model-informed precision dosing: A test\u2010case in tacrolimus dose adaptation for kidney transplant recipients. CPT: Pharmacometrics Syst Pharmacol. 2022;11:348\u201361. https:\/\/doi.org\/10.1002\/psp4.12758.","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"5214_CR17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","volume":"55","author":"E Brooks","year":"2016","unstructured":"Brooks E, Tett SE, Isbel NM, Staatz CE. Population pharmacokinetic modelling and bayesian estimation of tacrolimus exposure: Is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2016;55:1295\u2013335. https:\/\/doi.org\/10.1007\/s40262-016-0396-1.","journal-title":"Clin Pharmacokinet"},{"key":"5214_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/cpt.70090","volume":"119","author":"DRJ Kuypers","year":"2025","unstructured":"Kuypers DRJ, Annaert P, Jallah B, Naesens M, Teuns M, Laenen A, et al. Electronic patient file-embedded model\u2010informed precision dosing compared with physician dosing of tacrolimus in kidney transplantation. Clin Pharmacol Ther. 2025;119:381\u201392. https:\/\/doi.org\/10.1002\/cpt.70090.","journal-title":"Clin Pharmacol Ther"},{"key":"5214_CR19","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","volume":"99","author":"E St\u00f8rset","year":"2015","unstructured":"St\u00f8rset E, \u00c5sberg A, Skauby M, Neely M, Bergan S, Bremer S, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients \u2013 a prospective, randomized study. Transplantation. 2015;99:2158\u201366. https:\/\/doi.org\/10.1097\/TP.0000000000000708.","journal-title":"Transplantation"},{"key":"5214_CR20","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-024-01414-y","volume":"63","author":"Y Hoffert","year":"2024","unstructured":"Hoffert Y, Dia N, Vanuytsel T, Vos R, Kuypers D, Van Cleemput J, et al. Model-informed precision dosing of tacrolimus: A systematic review of population pharmacokinetic models and a benchmark study of software tools. Clin Pharmacokinet. 2024;63:1407\u201321. https:\/\/doi.org\/10.1007\/s40262-024-01414-y.","journal-title":"Clin Pharmacokinet"},{"key":"5214_CR21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"C-Y Zhao","year":"2016","unstructured":"Zhao C-Y, Jiao Z, Mao J-J, Qiu X-Y. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2016;81:891\u2013907. https:\/\/doi.org\/10.1111\/bcp.12830.","journal-title":"Br J Clin Pharmacol"},{"key":"5214_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s13318-021-00735-8","volume":"47","author":"J Methaneethorn","year":"2022","unstructured":"Methaneethorn J, Lohitnavy M, Onlamai K, Leelakanok N. Predictive performance of published tacrolimus population pharmacokinetic models in thai kidney transplant patients. Eur J Drug Metab Pharmacokinet. 2022;47:105\u201316. https:\/\/doi.org\/10.1007\/s13318-021-00735-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"5214_CR23","doi-asserted-by":"publisher","unstructured":"Nair SSNGR. Pharmacogenomics of CYP3A5 polymorphism: Predicting dose-adjusted trough levels of tacrolimus in south indian renal transplant patients. J Pharmacogenomics Pharmacoproteomics. 2016;7. https:\/\/doi.org\/10.4172\/2153-0645.1000161.","DOI":"10.4172\/2153-0645.1000161"},{"key":"5214_CR24","doi-asserted-by":"publisher","first-page":"726784","DOI":"10.3389\/fphar.2021.726784","volume":"12","author":"L Srinivas","year":"2021","unstructured":"Srinivas L, Gracious N, Nair RR. Pharmacogenetics based dose prediction model for initial tacrolimus dosing in renal transplant recipients. Front Pharmacol. 2021;12:726784. https:\/\/doi.org\/10.3389\/fphar.2021.726784.","journal-title":"Front Pharmacol"},{"key":"5214_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4103\/ijn.IJN_278_20","volume":"32","author":"TY Raj","year":"2022","unstructured":"Raj TY, Fernando ME, Srinivasa Prasad ND, Sujit S, Valavan KT, Harshavardhan TS, et al. Efficacy and outcomes of CYP3A5 genotype-based tacrolimus dosing compared to conventional body weight-based dosing in living donor kidney transplant recipients. Indian J Nephrol. 2022;32:240\u20136. https:\/\/doi.org\/10.4103\/ijn.IJN_278_20.","journal-title":"Indian J Nephrol"},{"key":"5214_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00210-009-0415-y","volume":"380","author":"R Singh","year":"2009","unstructured":"Singh R, Srivastava A, Kapoor R, Sharma K, Mittal RD. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of north india. Naunyn-Schmiedeberg\u2019s Archives Pharmacol. 2009;380:169\u201377. https:\/\/doi.org\/10.1007\/s00210-009-0415-y.","journal-title":"Naunyn-Schmiedeberg\u2019s Archives Pharmacol"},{"key":"5214_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1472-8206.2010.00917.x","volume":"26","author":"D Krishnakumar","year":"2012","unstructured":"Krishnakumar D, Gurusamy U, Dhandapani K, Surendiran A, Baghel R, Kukreti R, et al. Genetic polymorphisms of drug-metabolizing phase i enzymes CYP2E1, CYP2A6 and CYP3A5 in south indian population. Fundam Clin Pharmacol. 2012;26:295\u2013306. https:\/\/doi.org\/10.1111\/j.1472-8206.2010.00917.x.","journal-title":"Fundam Clin Pharmacol"},{"key":"5214_CR28","volume-title":"R: A language and environment for statistical computing [Internet]","author":"R Core Team","year":"2025","unstructured":"R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2025. https:\/\/www.R-project.org\/."},{"key":"5214_CR29","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan LD, Fran\u00e7ois R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"J Open Source Softw"},{"key":"5214_CR30","doi-asserted-by":"publisher","unstructured":"Rackauckas C, Ma Y, Noack A, Dixit V, Mogensen PK, Elrod C, et al. Accelerated predictive healthcare analytics with pumas, a high performance pharmaceutical modeling and simulation platform. https:\/\/doi.org\/10.1101\/2020.11.28.402297.","DOI":"10.1101\/2020.11.28.402297"},{"key":"5214_CR31","unstructured":"Rohatgi A. WebPlotDigitizer [Internet]. https:\/\/automeris.io\/."},{"key":"5214_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503\u201312. https:\/\/doi.org\/10.1007\/BF01060893.","journal-title":"J Pharmacokinet Biopharm"},{"key":"5214_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-023-01233-7","volume":"62","author":"M El Hassani","year":"2023","unstructured":"El Hassani M, Marsot A. External evaluation of population pharmacokinetic models for precision dosing: Current state and knowledge gaps. Clin Pharmacokinet. 2023;62:533\u201340. https:\/\/doi.org\/10.1007\/s40262-023-01233-7.","journal-title":"Clin Pharmacokinet"},{"key":"5214_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2125.2010.03837.x","volume":"71","author":"J Woillard","year":"2011","unstructured":"Woillard J, De Winter BCM, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and bayesian estimator for two tacrolimus formulations \u2013 twice daily prograf^(\u00ae) and once daily advagraf^(\u00ae). Br J Clin Pharmacol. 2011;71:391\u2013402. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03837.x.","journal-title":"Br J Clin Pharmacol"},{"key":"5214_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/bcp.13838","volume":"85","author":"LM Andrews","year":"2019","unstructured":"Andrews LM, Hesselink DA, Van Schaik RHN, Van Gelder T, De Fijter JW, Lloberas N, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2019;85:601\u201315. https:\/\/doi.org\/10.1111\/bcp.13838.","journal-title":"Br J Clin Pharmacol"},{"key":"5214_CR36","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2165\/11535950-000000000-00000","volume":"49","author":"K Benkali","year":"2010","unstructured":"Benkali K, Rostaing L, Premaud A, Woillard J-B, Saint-Marcoux F, Urien S, et al. Population pharmacokinetics and bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet. 2010;49:683\u201392. https:\/\/doi.org\/10.2165\/11535950-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"5214_CR37","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/bcp.13952","volume":"85","author":"Z Lu","year":"2019","unstructured":"Lu Z, Bonate P, Keirns J. Population pharmacokinetics of immediate- and prolonged\u2010release tacrolimus formulations in liver, kidney and heart transplant recipients. Br J Clin Pharmacol. 2019;85:1692\u2013703. https:\/\/doi.org\/10.1111\/bcp.13952.","journal-title":"Br J Clin Pharmacol"},{"key":"5214_CR38","doi-asserted-by":"publisher","first-page":"113225","DOI":"10.1016\/j.intimp.2024.113225","volume":"143","author":"L Han","year":"2024","unstructured":"Han L, Cui Y, Pan Y, Chen R, Jiao Z. External evaluation of tacrolimus population pharmacokinetic models in adult lung transplant patients: How to enhance the predictive ability of the model? Int Immunopharmacol. 2024;143:113225. https:\/\/doi.org\/10.1016\/j.intimp.2024.113225.","journal-title":"Int Immunopharmacol"},{"key":"5214_CR39","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/bcp.15091","volume":"88","author":"R Kirubakaran","year":"2022","unstructured":"Kirubakaran R, Hennig S, Maslen B, Day RO, Carland JE, Stocker SL. Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. Br J Clin Pharmacol. 2022;88:1751\u201372. https:\/\/doi.org\/10.1111\/bcp.15091.","journal-title":"Br J Clin Pharmacol"},{"key":"5214_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ekir.2019.09.013","volume":"5","author":"N Prasad","year":"2020","unstructured":"Prasad N, Jaiswal A, Behera MR, Agarwal V, Kushwaha R, Bhadauria D, et al. Melding pharmacogenomic effect of MDR1 and CYP3A5 gene polymorphism on tacrolimus dosing in renal transplant recipients in northern india. Kidney Int Rep. 2020;5:28\u201338. https:\/\/doi.org\/10.1016\/j.ekir.2019.09.013.","journal-title":"Kidney Int Rep"},{"key":"5214_CR41","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/cts.13153","volume":"15","author":"S Sahana","year":"2022","unstructured":"Sahana S, Bhoyar RC, Sivadas A, Jain A, Imran M, Rophina M, et al. Pharmacogenomic landscape of indian population using whole genomes. Clin Transl Sci. 2022;15:866\u201377. https:\/\/doi.org\/10.1111\/cts.13153.","journal-title":"Clin Transl Sci"},{"key":"5214_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/ijn.IJN_97_18","volume":"29","author":"ME Fernando","year":"2019","unstructured":"Fernando ME, Sellappan M, Srinivasa Prasad ND, Suren S, Thirumalvalavan K. Influence of CYP3A5 and ABCB1 polymorphism on tacrolimus drug dosing in south indian renal allograft recipients. Indian J Nephrol. 2019;29:261\u20136. https:\/\/doi.org\/10.4103\/ijn.IJN_97_18.","journal-title":"Indian J Nephrol"},{"key":"5214_CR43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00228-022-03323-0","volume":"78","author":"MI Francke","year":"2022","unstructured":"Francke MI, Visser WJ, Severs D, De Mik AME, Hesselink DA, De Winter BCM. Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients. Eur J Clin Pharmacol. 2022;78:1273\u201387. https:\/\/doi.org\/10.1007\/s00228-022-03323-0.","journal-title":"Eur J Clin Pharmacol"},{"key":"5214_CR44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ejhpharm-2012-000258","volume":"20","author":"A Johnston","year":"2013","unstructured":"Johnston A. Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. Eur J Hosp Pharm BMJ Specialist Journals. 2013;20:302\u20137. https:\/\/doi.org\/10.1136\/ejhpharm-2012-000258.","journal-title":"Eur J Hosp Pharm BMJ Specialist Journals"},{"key":"5214_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40262-020-00959-y","volume":"60","author":"P Marquet","year":"2021","unstructured":"Marquet P, Dest\u00e8re A, Monchaud C, R\u00e9rolle J-P, Buchler M, Mazouz H, et al. Clinical pharmacokinetics and bayesian estimators for the individual dose adjustment of a generic formulation of tacrolimus in adult kidney transplant recipients. Clin Pharmacokinet. 2021;60:611\u201322. https:\/\/doi.org\/10.1007\/s40262-020-00959-y.","journal-title":"Clin Pharmacokinet"},{"key":"5214_CR46","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","volume":"56","author":"F Andreu","year":"2017","unstructured":"Andreu F, Colom H, Elens L, Van Gelder T, Van Schaik RHN, Hesselink DA, et al. A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: A population approach. Clin Pharmacokinet. 2017;56:963\u201375. https:\/\/doi.org\/10.1007\/s40262-016-0491-3.","journal-title":"Clin Pharmacokinet"},{"key":"5214_CR47","doi-asserted-by":"publisher","unstructured":"Elens L, Capron A, van Schaik RHN, De Meyer M, De Pauw L, Eddour DC, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35(5):608\u201316. https:\/\/doi.org\/10.1097\/FTD.0b013e318296045b","DOI":"10.1097\/FTD.0b013e318296045b"},{"key":"5214_CR48","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/phar.2836","volume":"43","author":"JE Rower","year":"2023","unstructured":"Rower JE, McKnite A, Hong B, Daly KP, Hope KD, Cabrera AG, et al. External assessment and refinement of a population pharmacokinetic model to guide tacrolimus dosing in pediatric heart transplant. Pharmacotherapy. 2023;43:650\u20138. https:\/\/doi.org\/10.1002\/phar.2836.","journal-title":"Pharmacotherapy"},{"key":"5214_CR49","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bcp.12361","volume":"78","author":"E St\u00f8rset","year":"2014","unstructured":"St\u00f8rset E, Holford N, Hennig S, Bergmann TK, Bergan S, Bremer S, et al. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol. 2014;78:509\u201323. https:\/\/doi.org\/10.1111\/bcp.12361.","journal-title":"Br J Clin Pharmacol"},{"key":"5214_CR50","doi-asserted-by":"publisher","unstructured":"De Jonge H, Vanhove T, De Loor H, Verbeke K, Kuypers DRJ. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol. 2015;80(3):548\u201359. https:\/\/doi.org\/10.1111\/bcp.12703","DOI":"10.1111\/bcp.12703"},{"key":"5214_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E St\u00f8rset","year":"2014","unstructured":"St\u00f8rset E, Holford N, Midtvedt K, Bremer S, Bergan S, \u00c5sberg A. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2014;70:65\u201377. https:\/\/doi.org\/10.1007\/s00228-013-1584-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"5214_CR52","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Alarc\u00f3n B, Nolberger O, Vidal-Alabr\u00f3 A, Rigo-Bonnin R, Griny\u00f3 JM, Melilli E, et al. Guiding the starting dose of the once-daily formulation of tacrolimus in de novo adult renal transplant patients: A population approach. Front Pharmacol Front. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1456565.","DOI":"10.3389\/fphar.2024.1456565"},{"key":"5214_CR53","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/psp4.13056","volume":"12","author":"ZL Taylor","year":"2023","unstructured":"Taylor ZL, Poweleit EA, Paice K, Somers KM, Pavia K, Vinks AA, et al. Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing. CPT: Pharmacometrics Syst Pharmacol. 2023;12:1827\u201345. https:\/\/doi.org\/10.1002\/psp4.13056.","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"5214_CR54","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/cpt.659","volume":"101","author":"AS Darwich","year":"2017","unstructured":"Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny J, Marsousi N, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101:646\u201356. https:\/\/doi.org\/10.1002\/cpt.659.","journal-title":"Clin Pharmacol Ther"},{"key":"5214_CR55","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: A systematic review. Clin Pharmacokinet. 2020;59:1357\u201392. https:\/\/doi.org\/10.1007\/s40262-020-00922-x.","journal-title":"Clin Pharmacokinet"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05214-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05214-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05214-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:02:41Z","timestamp":1792429361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05214-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5214"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05214-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The primary prospective study for data collection was reviewed and approved by the Institutional Ethics Committee (IEC) of the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh (Reference number: INT\/IEC\/2022\/SPL-942\/23.08.2022). Subsequently, the secondary predictive performance analysis using de-identified data was approved as a separate study by the Institute Collaborative Research Committee (Reference number: PGI\/ICRC\/2023\/601\/01.03.2023). All participants provided informed consent to participate in the primary study, and the secondary analysis was conducted using de-identified datasets.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"618"}}